Weather for the Following Location: Knoxville on Map

University of Tennessee selects Orion Therapeutics for first $5M fund

"University startup investment concept"

Knoxville: University of Tennessee selects Orion Therapeutics for first $5M fund

The University of Tennessee Research Foundation has chosen Orion Therapeutics as the inaugural recipient of its $5 million fund dedicated to supporting startups that translate research from the university’s labs into commercial products.

Orion Therapeutics is revolutionizing drug delivery by harnessing the power of ribonucleic acid (RNA) to target specific areas within the body. RNA has become a vital component in medications and vaccines for various conditions, from muscular dystrophy to COVID-19.

Revolutionary Drug Delivery Technology

The technology developed by Orion Therapeutics focuses on addressing vascular diseases, particularly the accumulation of plaque in arteries. The company, founded in 2022 by a medical professor at UT and her former graduate student, is at the forefront of developing innovative solutions in the field of medicine.

Initial Funding and Support

Orion Therapeutics will receive $300,000 in funding, evenly distributed by the UT Research Foundation and Launch Tennessee. The UT Research Foundation’s Accelerate Fund, established in 2023, aims to empower companies that enter into licensing agreements to commercialize UT’s research.

Creating Opportunities for Tech Startups

Investments from the Accelerate Fund range from $20,000 to $150,000 and are open to UT-derived ideas, promoting innovation and entrepreneurship. While startups must originate from UT, founders are not required to be affiliated with the university.

Technology Transfer and Partnership

The UT Research Foundation, which operates independently from the university, plays a pivotal role in facilitating the transformation of cutting-edge research into marketable products. Collaborating with Orion Therapeutics demonstrates the foundation’s commitment to advancing UT innovations.

Potential for Breakthrough Medicines

Orion Therapeutics’ nanoparticle delivery system holds immense promise in the realm of drug development and vaccine delivery. The company’s technology offers limitless potential in treating a wide array of diseases by effectively transporting RNA to targeted sites within the body.

Advancing Biomedical Solutions

Co-founded by a seasoned professor and a visionary graduate student, Orion Therapeutics epitomizes the convergence of expertise and innovation. The company’s dedication to developing breakthrough medicines underscores its commitment to revolutionizing healthcare.

University of Tennessee selects Orion Therapeutics for first $5M fund

HERE Knoxville
Author: HERE Knoxville

Leave a Reply

Sign up for our Newsletter